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Breast-conserving surgery followed by radiotherapy is effective in reducing recurrence; however, telangiectasia and fibrosis can occur
as late skin side effects. As radiotherapy acts through producing DNA damage, we investigated whether genetic variation in DNA
repair and damage response confers increased susceptibility to develop late normal skin complications. Breast cancer patients who
received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up
time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response
(TP53, P21) were determined. Associations between telangiectasia and genotypes were assessed among 409 patients, using
multivariate logistic regression. A total of 131 patients presented with telangiectasia and 28 patients with fibrosis. Patients with variant
TP53 genotypes either for the Arg72Pro or the PIN3 polymorphism were at increased risk of telangiectasia. The odds ratios (OR)
were 1.66 (95% confidence interval (CI): 1.02–2.72) for 72Pro carriers and 1.95 (95% CI: 1.13–3.35) for PIN3 A2 allele carriers
compared with non-carriers. The TP53 haplotype containing both variant alleles was associated with almost a two-fold increase in risk
(OR 1.97, 95% CI: 1.11–3.52) for telangiectasia. Variants in the TP53 gene may therefore modify the risk of late skin toxicity after
radiotherapy.
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Radiotherapy is commonly applied after breast-conserving surgery
to reduce the risk of locoregional recurrence of breast cancer and
has been shown to be as effective as radical mastectomy (Fisher
et al, 2002). Although standard radiation therapy is well tolerated
by the majority of patients, late normal tissue complications
arising from the intrinsic sensitivity of normal tissue, and
correlated poor cosmetic results, remain as health concerns of
treated breast cancer patients over time (Cetintas et al, 2002;
Deutsch and Flickinger, 2003; Smith and Ross, 2004). The process
of endothelium reconstruction is radiation dose-dependent,
progresses over months and years and leads to increases in the
severity of both telangiectasia and fibrosis (Bentzen et al, 1989;
Archambeau et al, 1995; Chen et al, 2006). Telangiectasias are
small dilated blood vessels near the surface of the skin and fibrosis
is the development of excess fibrous connective tissue leading to
induration. There is, however, considerable inter-individual
variability in the development of adverse reactions in normal
tissue of irradiated patients. Besides duration, radiation dose and
schedule (Turesson et al, 1996; Hill et al, 2001), patient-related
factors, such as age, acute skin reaction and lifestyle factors
(Bentzen and Overgaard, 1991; Bentzen et al., 1996; Turesson et al,
1996; Johansen et al, 2002; Deutsch and Flickinger, 2003; Chen
et al, 2006; Lilla et al, 2007), as well as genetic susceptibility
(Bentzen and Overgaard, 1994; Chang-Claude et al, 2005;
Andreassen et al, 2006; Popanda et al, 2008) have been implicated.
Sensitivity to radiation exposure is suggested to be a complex,
polygenic trait, which results from the interaction of a number of
genes in different cellular pathways (Travis, 2007).
As radiation therapy exerts its cytotoxic effects through damage
to cells, proteins and DNA, the individual capacity to repair
damaged DNA may modify the response of the normal tissue.
Radiation-induced DNA damage is diverse and therefore nearly all
DNA repair pathways might be involved in its removal, especially
repair of double-strand breaks through mechanisms such as
homologous recombination and non-homologous end joining
(Jeggo and Lobrich, 2006). In addition, nucleotide and base-
excision repair play an important role, mainly in the repair of
oxidative DNA damage (Hoeijmakers, 2001).
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requires the expression and activity of the p53 pathway (Gudkov
and Komarova, 2003). The p53 protein is activated through
phosphorylation by radiation DNA damage-induced kinases,
including ataxia telangiectasia-mutated and the DNA-dependent
protein kinase (Banin et al, 1998; Fei and El-Deiry, 2003; Schwartz,
2007). Activated p53 protein has various downstream targets,
including genes involved in cell-cycle regulation, apoptosis, and
DNA repair. Regulation of these processes by p53 controls the
cellular response to ionising radiation-induced damage. p21 is a
critical cell-cycle checkpoint gene, regulated tightly by p53. As
soon as DNA is damaged by radiation, binding of p53 protein
induces transcription of the downstream gene p21, which stops
cells from entering into the S phase (Robles et al, 2002). p21,
together with p53, is directly involved in G1/S checkpoint control
in response to ionising radiation (Dotto, 2000).
We therefore evaluated the association between several putative
functional polymorphisms in six genes involved in DNA repair and
two damage response genes and development of late normal tissue
complications in a prospective study of breast cancer patients who
received radiotherapy after breast-conserving surgery.
MATERIAL AND METHODS
Patient population and data collection
The methods of this study have been described earlier (Twardella
et al, 2003; Chang-Claude et al, 2005; Lilla et al, 2007). Briefly,
women diagnosed with breast cancer who received radiotherapy
after breast-conserving surgery were enrolled between June 1998
and March 2001 from four radiotherapy units in Germany
(Women’s Clinic at the University of Heidelberg, St Vincentius
Clinic in Karlsruhe, City Hospital in Karlsruhe and University
Hospital of Mannheim). Patients who received chemotherapy before
or during radiation were not eligible for the study. Information on
demographic factors, medical history, and lifestyle factors was
obtained through self-administered questionnaires. Details on
clinical tumor characteristics and treatment regimen were ab-
stracted from patient records. Informed consent was obtained from
all participants, and the study was approved by the ethics committee
of the University of Heidelberg, the Institutional Review Board for
Roswell Park Cancer Institute, and the US Army Medical Research
and Materiel Command Human Subjects Research Review Board.
Breast irradiation
Details on the radiotherapy regimen (total dose, dose per fraction,
treatment time, boost dose) were abstracted from the irradiation
protocols. As described earlier (Twardella et al, 2003), all patients
received a common breast irradiation treatment with conformal
tangential irradiation with lateral and medial wedge fields,
including CT-based planning, simulation, verification, and quality
assurance. At three hospitals, the standard regimen included
irradiation of the whole breast, either 50Gy given in 5 2.0Gy
fractions or 50.4Gy in 5 1.8Gy fractions per week, followed by a
photon or electron boost with doses ranging from 5 to 20Gy. Three
patients were treated with brachytherapy (20 or 25Gy). In the
fourth radiation department, patients received 56Gy of whole
breast irradiation in 5 2.0Gy fractions without boost. The
biologically effective dose (BED) of radiotherapy relative to an
irradiation with a fraction dose of 2.0Gy, that is the normalised
total dose (NTD), was calculated to account for differences in
fractionation according to the following formula:
NTD ¼
BED
1 þ 2GY=ða=bÞ
¼ n:d:
ð1 þ d=ða=bÞÞ
ð1 þ 2GY=ða=bÞÞ
given the number of fractions n, the fraction size of d, and an a/b
ratio of 3Gy for telangiectasia and 2Gy for fibrosis.
Follow-up and evaluation of toxicities
The occurrence of acute side effects of radiotherapy was monitored
and documented by physicians several times during the study. We
have earlier reported on acute radiation-induced toxicity, defined
as grade 2c and above (at least one moist desquamation or
interruption of radiotherapy due to toxicity), in this patient cohort
(Twardella et al, 2003; Chang-Claude et al, 2005; Ambrosone et al,
2006; Popanda et al, 2006; Tan et al, 2006). Patients were
recontacted between June 2003 and July 2005 to assess the
occurrence of late adverse effects of radiotherapy and course of
disease (relapse, metastases, secondary carcinoma, and death). A
self-administered questionnaire similar to that applied at baseline
was used to collect information on demographic and epidemio-
logical risk factors, and to record behavior changes that may have
occurred after radiotherapy. Patients were examined by the study
physician or the treating physician to assess the occurrence of late
adverse effects of radiotherapy.
The late side effects were classified according to the RTOG/
EORTC late radiation morbidity scoring schema (Seegenschmiedt,
1998) supplemented by LENT-SOMA scores. Patients’ general
condition, weight changes, nausea and development of lymphatic
edema (arm or breast), and adverse reactions of the skin
(telangiectasia), subcutaneous tissue (fibrosis) and other organ
tissues (heart, lung, larynx) were recorded. The severity of late
effects was scored from 0 to 4, whereby the development of side
effects of scores X2 was considered to indicate late normal tissue
complications.
Genotyping assays
Most polymorphisms (see Table 2) were detected by amplification
with real-time PCR followed by melting-curve analysis
with fluorescence-labeled hybridisation probes in a LightCycler
(Roche Diagnostics, Mannheim, Germany) as described earlier
(Chang-Claude et al, 2005; Popanda et al, 2006; Tan et al, 2006).
The oligonucleotides for analysis of the XRCC1 -77 polymorphism
(rs3213245) were the PCR primers (sense) 50-ctttagccagcgcaggtcg-
30OH and (antisense) 50-ccccatgcaggtccctcac-30OH, sensor
50-cccgccccctcccactc-30-FL and anchor 50-LC Red640-ccctgcccct
cggaccccatactc-30P. The sense primer included a mismatch to avoid
stem loops in the amplicon because of the high and repetitive G/C
content of the target sequence. PCR primers and probes were
designed with the help of Tib Molbiol (Berlin, Germany).
Annealing temperature of the primers was 601C. The PCR was
performed for all polymorphisms with Qiagen reagents (Qiagen,
Hilden, Germany) in a volume of 10ml using 10ng of DNA. Overall,
10% randomly selected samples were analysed by conventional
PCR-RFLP to verify the LightCycler results; 100% concordance was
found. The insertion of the TP53 PIN3 polymorphism was
identified by standard PCR and electrophoresis (Tan et al, 2006).
A negative control containing all the reagents but with water
instead of the DNA template was included in every amplification
set. All genotyping assays were carried out blinded to the clinical
diagnosis. For each polymorphism, PCR fragments of the
homozygous wild-type allele, the homozygous variant allele, and
one heterozygous sample were sequenced.
Statistical analysis
Significant differences in distribution of genotypes by presence of
late skin toxicities (scores X2) were tested by the w
2 and Fischer’s
exact tests. Each polymorphism was tested for deviation from
Hardy–Weinberg equilibrium by comparing the observed and
expected genotype frequencies using the w
2-test with one degree of
freedom. Multivariate unconditional logistic regression analysis
was used to assess the association of genotypes with occurrence of
late complications of radiotherapy. Odds ratios (OR) and 95%
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procedure in SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
Possible effect modification of genotype associations by other
covariables was evaluated by the log likelihood ratio test
comparing models with and without the first-order interaction
terms. All tests were two-sided and considered to be statistically
significant with a P-value of p0.05. The logistic regression analysis
was performed only for the occurrence of telangiectasia, excluding
seven patients who developed fibrosis with a score X2 but not
telangiectasia. Multivariate models included NTD, age at the time
of late toxicity evaluation, and follow-up time since end of
radiotherapy. Stepwise backward elimination with Pp0.03 as
threshold was used to develop a final model to control for potential
confounders. The final model included, in addition hospital
facility, acute skin toxicity, a history of hypertension and allergy,
skin type (three categories), pack-years of smoking (0, 1–19,
X20), and marital status.
Analyses to assess association between haplotypes and risk for
telangiectasia were carried out using the function haplo.glm of the
R package haplo.stats, which uses a generalised linear model (glm)
allowing for an ambiguous linkage phase (Lake et al, 2003). The
most common haplotype was used as the referent. Possible effect
modification of haplotype associations by other covariables were
evaluated by the likelihood ratio test. As this was a hypothesis
generating study, significance level was defined at Po0.05
although 13 SNPs were tested.
Results
Data on late effects of radiotherapy as well as information on
demographic and epidemiological factors were available for 421
breast cancer patients, as reported earlier (Lilla et al, 2007;
Kuptsova et al, 2008). After a median follow-up time of 51 months
(range 36–77 months), the most common symptoms of scores X2,
which were observed included telangiectasia (32.1%), impairment
of the general condition (15.9%), fibrosis (7.1%), lymphatic edema
in the arm and breast (6.2%), and pain (5.5%). Of 416 patients
(after excluding 3 patients treated with interstitial boost and 2
patients with missing information on fibrosis), 131 patients
presented with telangiectasia and 28 with fibrosis of grades X2,
whereby 21 patients presented with both adverse reactions.
Characteristics of the 409 breast cancer patients who also had
genotype data and were included in this analysis (excluding the
seven patients presenting with fibrosis only) are shown in Table 1.
We found a significant association between genetic polymorph-
isms in the TP53 gene and risk for telangiectasia (Table 2).
Compared with non-carriers, patients carrying the variant TP53
72Pro allele had an increased risk of adverse effects (OR of 1.66,
95% CI: 1.02–2.72). Carriers of the TP53 PIN3 A2 allele were also
at increased risk of telangiectasia (OR 1.95, 95% CI: 1.13–3.35).
None of the other genetic polymorphisms studied showed
significant associations with occurrence of telangiectasia.
Strong association (linkage disequilibrium) was found between
the TP53 Arg72Pro and TP53 PIN3 polymorphisms (Po0.001). We
therefore investigated haplotype effects of the two TP53 poly-
morphisms. Compared with the common ArgA1 haplotype, the
ProA2 haplotype containing both variant alleles was associated
with a significantly increased OR of 1.97 (95% CI: 1.11–3.52) for
telangiectasia (Table 3). Haplotype association analysis for the
XRCC1 and XPD genes with data for at least two genetic
polymorphisms did not reveal further significant findings.
Further analysis for effect modification yielded differences in the
effect of TP53 on risk for telangiectasia, according to occurrence of
acute skin toxicity (moist desquamation). Thirty women (22.9%)
had presented with acute skin toxicity during radiotherapy in
patients with telangiectasia, and 45 women (16.2%) in those
without telangiectasia. The elevated risk of telangiectasia
associated with the TP53 ProA2 haplotype was found only in
patients who did not present with acute toxicity during radio-
therapy (OR 2.78, 95% CI: 1.44–5.35) and not in those who
experienced acute skin toxicity during radiotherapy
(Pheterogeneity¼0.06) (Table 3).
DISCUSSION
In this study of breast cancer patients treated with radiotherapy
after breast-conserving surgery, we found that variants of TP53
were associated with an increased risk for developing telangiecta-
sia after radiation therapy. Although both variants, TP53 72Pro
and PIN3 A2, were associated with elevated risk, the haplotype
results suggested that cis effects of the two variants may be most
relevant.
Two of the many p53 functions may be important in modulating
radiosensitivity. Growth arrest mediated by p53 plays an important
role in inhibiting mitotic cell death in epithelia of the small
intestine of mice and, thus, is thought to reduce radiation toxicity
in these animals (Komarova et al, 2004). Also, apoptosis and cell
death by mitotic catastrophe have been recognised as an important
response to radiation in many cells (Dewey et al, 1995; Weber and
Wenz, 2002; Komarova et al, 2004) as they remove heavily
Table 1 Clinical and demographic characteristics of the breast cancer
patients
Characteristics Mean (s.d.) Range
Age late toxicities (years)
a 60.6 (8.57) 27–88
Age radiotherapy (years)
b 64.7 (8.59) 31–91
Total radiation dose (Gy)
c 61.8 (4.10) 51–71
Follow-up time (months) 51.4 (6.81) 36–77
Frequency Percent
Body mass index (kg/m
2)
o25 182 44.5
25–30 161 39.4
430 66 16.1
Tumor stage status
In situ 36 8.8
1 277 67.7
2 92 22.5
Other or unknown 1 0.2
Lymph node status
0 314 76.8
1 57 13.9
Unknown 38 9.3
Metastasis status
0 261 63.8
1 1 0.2
Unknown 147 35.9
Boost therapy type
Photon 275 67.2
Electron 94 23.0
No boost 40 9.8
Radiotherapy clinic
University of Heidelberg
Women’s Clinic
228 55.8
Karlsruhe St Vincentius clinic 96 23.5
Karlsruhe City Hospital 60 14.7
University Hospital of Mannheim 25 6.1
aAge at the time of late toxicities evaluation.
bAge at the end of radiation therapy.
cIncludes irradiation to the whole breast and boost application.
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sTable 2 Association between polymorphisms in DNA repair and cell-cycle genes and risk of developing late skin toxicity (telangiectasia) with score X2
after radiotherapy
Patients without telangiectasia Patients with telangiectasia
Gene polymorphism Genotype N¼278 % N¼131 % OR
a 95% CI
APEX1 TT 71 25.9 39 30.7 1.00
Asp148Gln TG 134 48.9 65 51.2 1.03 0.58–1.83
rs3136820 GG 69 25.2 23 18.1 0.66 0.33–1.32
TG+GG 203 74.1 88 69.3 0.90 0.53–1.54
XRCC1 TT 94 34.2 43 33.9 1.00
 77 T4C TC 136 49.5 54 42.5 0.97 0.56–1.67
rs3213245 CC 45 16.4 30 23.6 1.87 0.94–3.70
TC+CC 181 65.8 84 66.1 1.17 0.71–1.95
XRCC1 CC 242 88.3 117 92.1 1.00
Arg194Trp CT 30 11 10 7.9 0.58 0.24–1.40
rs1799782 TT 2 0.7 0 0 0 0
CT+TT 32 11.7 10 8 0.57 0.24–1.38
XRCC1 GG 244 88.4 118 92.9 1.00
Arg280His GA 30 10.9 9 7.1 0.49 0.19–1.24
rs25489 AA 2 0.7 0 0 0 0
GA+AA 32 11.6 9 7.1 0.43 0.17–1.09
XRCC1 GG 112 40.6 50 39.4 1.00
Arg399Gln GA 120 43.5 63 49.6 1.09 0.65–1.82
rs25487 AA 44 15.9 14 11 0.63 0.29–1.37
GA+AA 164 59.4 77 60.6 0.96 0.59–1.57
XRCC2 GG 236 85.5 113 89 1.00
Arg188His GA 38 13.8 13 10.2 0.83 0.39–1.76
rs3218536 AA 2 0.7 1 0.8 1.05 0.08–13.93
GA+AA 40 14.5 14 11 0.84 0.41–1.74
XRCC3 CC 104 38 45 35.4 1.00
Thr241Met CT 126 46 63 49.6 1.05 0.62–1.79
rs861539 TT 44 16.1 19 15 1.12 0.53–2.40
CT+TT 170 62 82 64.6 1.07 0.65–1.77
NBS1 GG 120 43.5 53 41.7 1.00
Glu185Gln GC 137 49.6 58 45.7 0.92 0.55–1.54
rs1805794 CC 19 6.9 16 12.6 2.14 0.88–5.19
GC+CC 156 56.5 74 58.3 1.06 0.65–1.72
XPD GG 120 43.8 42 33.3 1.00
Asp312Asn GA 117 42.7 69 54.8 1.51 0.89–2.55
rs1799793 AA 37 13.5 15 11.9 0.91 0.41–2.01
GA+AA 154 56.2 84 66.6 1.36 0.82–2.24
XPD AA 109 39.6 42 33.3 1.00
Lys751/Gln AC 133 48.4 65 51.6 1.15 0.68–1.95
rs13181 CC 33 12 19 15.1 1.21 0.57–2.58
AC+CC 166 60.4 84 66.6 1.16 0.70–1.92
P21 CC 242 87.7 110 86.6 1.00
Ser31Arg CA 31 11.2 17 13.4 1.54 0.71–3.32
rs1801270 AA 3 1.1 0 0 0 0
CA+AA 34 12.3 17 13.4 1.27 0.60–2.68
TP53 GG 160 58.0 64 50.4 1.00
Arg72Pro GC 96 34.8 49 38.6 1.67 0.98–2.83
rs1042522 CC 20 7.3 14 11 1.62 0.71–3.70
GC+CC 116 40 63 49.6 1.66 1.02–2.71
TP53 A1A1 214 77.6 87 68.5 1.00
PIN3 A1A2 56 20.3 40 31.5 2.14 1.23–3.71
A2A2 6 2.2 0 0 0 0
A1A2+A2A2 62 22.4 40 31.5 1.95 1.13–3.37
CI¼confidence interval; NTD¼normalised total dose; OR¼odds ratio.
aAdjusted for NTD, age at the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin
toxicity, high blood pressure, allergy, pack-years (never, o20, X20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).
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variants in codon 72 showed that this polymorphism might
modulate these two responses. The 72Arg form induced apoptosis
more efficiently than the 72Pro form. In contrast, the 72Pro form
appeared to induce a higher level of G1 arrest than the 72Arg form
giving time to repair (Thomas et al, 1999; Dumont et al, 2003; Pim
and Banks, 2004). Consequently, the 72Pro p53 protein was found
to be more efficient in specifically activating p53-dependent DNA
repair target genes, and cells carrying the 72Pro allele had
significantly higher DNA repair capacity (Siddique and Sabapathy,
2006). Although it is unclear which of the functional differences
between the codon 72 polymorphic alleles is more important, our
results could be explained by the lower efficiency with which the
72Pro form induced apoptosis of heavily damaged cells after
radiation. Repair and reconstitution of the normal tissue function
might be incomplete over time in the presence of these cells,
leading to late adverse effects which become visible as telangiecta-
sia, a disturbance of the blood vessels.
We also observed an independent effect of the TP53 PIN3
polymorphism on the risk of late radiation toxicity, but the results
of the haplotype analysis suggested the strongest effect on risk
conferred by the haplotype containing both variant alleles. The
functional significance of TP53 PIN3 has remained largely
unexplored. Our haplotype analysis revealed further that the
strongest risk effect of the 72ProA2 haplotype was visible in
patients who did not develop severe acute side effects during
radiotherapy. We proposed that the Pro allele carriers experienced
reduced cell loss by apoptosis and, potentially, mitotic catastrophe
during therapy and were, thus, protected from severe acute side
effects as we found in our analysis of acute side effects (Tan et al,
2006). This protective effect may turn out as a risk factor for late
side effects when the irradiated tissue is observed over a longer
time. More analyses of the in vivo and in vitro effects of the TP53
Arg72Pro and PIN3 polymorphisms are needed, however, before
we can apply these TP53 variants as predictive markers for late
side effects of radiotherapy.
p21 plays a direct role in mediating irradiation-induced G1
arrest, with p53 as the transcription factor in this process. This
mechanism indicates a possible combined effect of polymorphisms
in the two genes. However, p53 may modulate response to
radiation damage in the G1 phase of the cell cycle through
mechanisms independent of p53-mediated transcriptional activa-
tion of p21 and cell-cycle arrest (Mazzatti et al, 2005). We did not
observe a significant effect of p21 Ser31Arg polymorphism on the
risk of late skin toxicity. Other studies also failed to find an
association of this variant with risk or prognosis of breast cancer
(Keshava et al, 2002; Azzato et al, 2008).
In addition, ten polymorphisms causing an amino acid change
in six different DNA repair genes were investigated for associations
with telangiectasia, but no significant effects were detected. The
XRCC1 Arg399Gln polymorphism has been reported to be
associated with telangiectasia but not with fibrosis, particularly
in patients who did not receive a boost, albeit based on 167
patients of whom 39 presented with telangiectasia (Giotopoulos
et al, 2007). This polymorphism was also not found to be
associated with severe grade 3 fibrosis after irradiation of the
breast (Andreassen et al, 2006). A further study, which did not
differentiate between early and late adverse reaction to radio-
therapy, reported an elevated risk in women carrying both the
variant alleles of the Arg194Trp and the Arg399Gln polymorph-
isms (Moullan et al, 2003) and a protective effect for the T-C-G-G
haplotype determined by all four XRCC1 genetic polymorphisms,
-77T4C, Arg194Trp, Arg280His, and Arg399Gln (Brem et al,
2006). Although the results appear divergent, the studies differ in
the specific type(s) of adverse reactions being studied, the length of
follow-up for side effects, and adjustment for patient-related
factors; therefore, comparison of the findings is problematic.
Polymorphisms in XRCC3 and APEX1 were studied in breast
cancer patients receiving radiotherapy (summarised in Chistiakov
et al, 2008; Popanda et al, 2008). Consistent with our null results,
all of these studies failed to show a contribution of these SNPs to
the risk of adverse reactions after radiotherapy, implying that they
may not be promising candidates for predicting late radio-
sensitivity.
To our knowledge, this is the first epidemiological study on the
two TP53 genetic variants as predictors of late tissue reactions to
radiation therapy. However, both the TP53 codon 72 and intron 3
variants have been found to be associated with poorer prognosis of
non-small cell lung cancer (Boldrini et al, 2008). Patients receiving
chemoradiotherapy for advanced head and neck cancer were found
to have higher response rates and survival when their tumors
expressed the proapoptotic 72 Arg allele (Sullivan et al, 2004).
This study has a number of strengths. Breast cancer patients
from this cohort were treated similarly, with radiation dosage
carefully assessed, and patients were followed prospectively.
Improved radiation techniques at the time of patient recruitment,
as well as retrieval of individual irradiation dose methods and
records, allowed for proper calculations of BED. The phenotype
was precisely defined using the standardised scoring system for
late toxicity. In addition, we accounted for patient- and treatment-
related factors that influenced risk for telangiectasia when
assessing the effect of the genetic variants.
Both telangiectasia and subcutaneous fibrosis are among the
most common long-term skin side effects of radiation therapy.
Table 3 Reconstructed haplotypes and the association with risk of
developing late skin toxicity (telangiectasia) with score X2 after radio-
therapy
Gene Haplotype Frequency OR
a 95% CI
All patients
TP53 GA1 0.71 1
GA2 0.03 1.02 0.29–3.63
CA1 0.16 1.20 0.79–1.82
CA2
b 0.11 1.97 1.11–3.52
Patients without acute toxicity during radiotherapy
c
TP53 GA1 0.71 1
GA2 0.02 0.68 0.13–3.60
CA1 0.16 1.15 0.71–1.85
CA2 0.12 2.78 1.44–5.37
Patients with acute toxicity during radiotherapy
TP53 GA1 0.71 1
GA2 0.04 1.10 0.09–13.41
CA1 0.17 1.47 0.52–4.17
CA2 0.09 0.52 0.11–2.53
All patients
XRCC1 CCGG 0.41 1
TCGG 0.12 1.15 0.66–2.00
TCGA 0.36 0.78 0.53–1.15
TTGG 0.05 0.51 0.21–1.24
Rare
d 0.07 0.56 0.26–1.20
XPD GA 0.56 1
GC 0.09 1.25 0.64–2.46
AA 0.06 1.14 0.55–2.38
AC 0.29 1.09 0.74–1.62
CI¼confidence interval; NTD¼normalised total dose; OR¼odds ratio.
aAdjusted
for NTD, age the time of late toxicities evaluation, time since radiotherapy (months),
clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, o20, X20),
skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/
widowed, married/partner).
bA2 allele carries a duplication of 16bp in intron 3.
cP¼0.06 for effect heterogeneity according to occurrence of acute skin toxicity.
dComposed of haplotypes with frequencies below 5%.
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various skin layers involved and thereby possible differing genetic
susceptibility, we opted to restrict the present analysis to
telangiectasia because of the limited occurrence of fibrosis and
therefore restricted power. Progressive nature of these complica-
tions, together with longer time to follow-up, may permit later
analyses of late normal tissue complications in this cohort in the
future.
In conclusion, this prospective study showed that variants in the
TP53 gene are associated with risk of late skin toxicity after
accounting for patient-related factors and treatment modalities. As
this is the first report on the involvement of p53 in late skin
adverse effects, replication of these findings in other studies is
encouraged. Advances in the search for biomarkers of radiation-
induced late skin side effects may lead to improved treatment
choices for breast cancer patients, and improve cosmetic outcome
as well as quality of life after surviving breast cancer.
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